Michael Seckl
Imperial College London
Hammersmith and Charing Cross Hospitals
Fulham Palace Road
London
W6 8RF
United Kingdom
Email: m.seckl@imperial.ac.uk
Tel: 020 3311 1421
Web: Lab website
About Michael Seckl
World-class scientist Professor Michael Seckl works at the Hammersmith and Charing Cross Hospitals, part of Imperial College London. He is leading a clinical trial called LungStar, for people with small cell lung cancer (SCLC). He is also investigating how some lung cancers become resistant to chemotherapy. Professor Seckl co-ordinates lab studies into the disease and uses his findings to improve treatments for patients.
Michael Seckl other research projects
Funding period: 01 January 2011 to 30 June 2014
New Agents Committee Trials Funding
Funding period: 01 May 2011 to 31 October 2013
Recent publications
Overexpression of the Mammalian Target of Rapamycin A Novel Biomarker for Poor Survival in Resected Early Stage Non-small Cell Lung Cancer
J Thorac Oncol.2010;5 :314-319
The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo
Cancer Res.2009;69 :8645-8651
